key: cord-0873430-q3db7v16 authors: Pavot, Vincent; Berry, Catherine; Kishko, Michael; Anosova, Natalie G.; Huang, Dean; Tibbitts, Tim; Raillard, Alice; Gautheron, Sylviane; Gutzeit, Cindy; Koutsoukos, Marguerite; Chicz, Roman M.; Lecouturier, Valerie title: Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates date: 2022-03-31 journal: Nat Commun DOI: 10.1038/s41467-022-29219-2 sha: 39104350d33f4b0d39471c3d46c959d13d83b902 doc_id: 873430 cord_uid: q3db7v16 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that partly evade neutralizing antibodies raises concerns of reduced vaccine effectiveness and increased infection. We previously demonstrated that the SARS-CoV-2 spike protein vaccine adjuvanted with AS03 (CoV2 preS dTM-AS03) elicits robust neutralizing antibody responses in naïve subjects. Here we show that, in macaques primed with mRNA or protein-based subunit vaccine candidates, one booster dose of CoV2 preS dTM-AS03 (monovalent D614 or B.1.351, or bivalent D614 + B.1.351 formulations), significantly boosts the pre-existing neutralizing antibodies against the parental strain from 177- to 370-fold. Importantly, the booster dose elicits high and persistent cross-neutralizing antibodies covering five former or current SARS-CoV-2 variants of concern (Alpha, Beta, Gamma, Delta and Omicron) and, unexpectedly, SARS-CoV-1. Interestingly, we show that the booster specifically increases the functional antibody responses as compared to the receptor binding domain (RBD)-specific responses. Our findings show that these vaccine candidates, when used as a booster, have the potential to offer cross-protection against a broad spectrum of variants. This has important implications for vaccine control of SARS-CoV-2 variants of concern and informs on the benefit of a booster with the vaccine candidates currently under evaluation in clinical trials. E mergence of severe acute respiratory-syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOC), such as Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) in late 2020 and lastly Omicron (B.1.1.529) in November 2021 have sparked concerns due to their higher transmissibility and/or pathogenicity [1] [2] [3] [4] . These VOC harbor specific mutations in the spike proteins impacting the transmission and antigenicity reflecting growing immune pressure at positions shown to involve antibody recognition 5 . Some VOC (Beta, Gamma, Delta, and Omicron) have also demonstrated partial evasion of natural and vaccine-elicited neutralizing antibodies [6] [7] [8] [9] [10] and are associated with reduction of vaccine effectiveness [11] [12] [13] . In response to the rapid evolution of SARS-CoV-2 and the global circulation of VOC since the end of 2020, vaccines are being developed using a modified spike antigen containing the mutations identified in Beta, Delta, and Omicron variants (NCT04785144) [14] [15] [16] . This strategy is based on the influenza-vaccine model where the vaccine is modified yearly according to the epidemiology, likewise, a combination of spike antigens covering multiple cocirculating strains may be necessary. In early 2021, the Beta spike (B.1.351) was selected, as it displayed the greatest breakthrough infections against the parental (D614) vaccines 11, 12 , before Omicron was shown to cause even higher levels of vaccine escape. Considering the risk of waning immunity after natural infection or immunization and the risk of vaccine escape by emerging variants, the key attributes of future vaccines will be the ability to boost, prolong, and broaden protective immunity against new emerging variants. Here we formulated soluble prefusion-stabilized spike trimers (CoV2 preS dTM) with the well-characterized adjuvant AS03, an oil-in-water emulsion composed of α-tocopherol, squalene, and polysorbate 80 17 . AS03 has been shown to potently induce antibody responses, increase vaccine durability, promote heterologous strain cross-reactivity, and has dose-sparing effects 18, 19 . We previously reported that CoV2 preS dTM-AS03 (D614) confers protective efficacy against SARS-CoV-2 (D614 strain) challenge in nonhuman primates (NHPs) and the vaccineinduced IgG mediated protection from SARS-CoV-2 challenge following passive transfer to hamsters 20 . We also showed safety and immunogenicity of an optimized vaccine formulation in humans in a phase-2 clinical trial 21 and the vaccine formulation is being assessed as a booster vaccine (NCT04762680) and for efficacy (NCT04904549) in phase-3 clinical studies. In this work, the objective was to assess a protein-based subunit vaccine booster in macaques vaccinated 7 months before with either mRNA-LNP or subunit CoV2 preS dTM-AS03 Sanofi vaccine candidates. Various formulations, namely AS03adjuvanted parental (D614), variant (B.1.351), and bivalent (D614 + B.1.351) CoV2 preS dTM or non-adjuvanted CoV2 preS dTM (B.1.351), were evaluated for their ability to boost neutralizing antibodies (NAbs) against the parental strain and to induce cross-neutralization against the five VOC described so far (Alpha, Beta, Gamma, Delta, and Omicron) and SARS-CoV-1 (from the 2003 outbreak) to further explore the breadth of neutralization. Boosting with homologous or heterologous formulations of CoV2 preS dTM led to significant increase in neutralizing antibodies against parental SARS-CoV-2, with a significant AS03-adjuvant effect. Following primary vaccination with either mRNA-LNP or CoV2 preS dTM-AS03 (Fig. 1a) , we assessed the neutralizing antibody (NAb) responses against the parental D614G strain. Using a GFP-based pseudovirus-neutralization assay, the mean NAb titers at day 35 (D35, 2 weeks post-dose 2) against the parental pseudovirus were 2.6 log 10 for the mRNA-primed cohort and 2.9 log 10 for the subunit-primed cohort (Fig. 1b) . Seven months post prime (baseline pre-boost), mean parental NAb titers declined to 1.4 log 10 for the mRNAprimed cohort and to 2.2 log 10 for the subunit-primed cohort. For comparison, the mean D614 NAb titer in a panel of 93 human convalescent sera (collected within 3 months after positive PCR test) was 2.0 log 10 (D614 and D614G NAb titers were shown to be similar in a concordance analysis, Supplementary Fig. 1 ) and the WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human) (National Institute for Biological Standards and Control (NIBSC) code: 20/136) had a titer of 2.8 log 10 . A booster dose with non-adjuvanted CoV2 preS dTM (B.1.351) significantly increased parental NAb titers compared with baseline as soon as 7 days after injection, reaching a plateau between 14 and 28 days in both mRNA-primed (mean of 3.3 log 10 ) and subunit-primed (mean of 3.5 log 10 ) cohorts (pvalue < 0.001), and then slightly decreased up to 3 months post booster (mean of 2.6 and 2.8 log 10 in mRNA-primed and subunitprimed cohorts, respectively). As in each cohort, macaques were randomized for their baseline titers 6 months post-primary vaccination and peak titers post-prime (D35), we analyzed the fold-increase of NAb titers 14 days post-booster compared with baseline or post-prime. Compared with baseline, mean increase in NAbs were 60-fold (p-value < 0.001) in mRNA-primed and 16fold (p-value < 0.001) in subunit-primed cohorts. Of note, baseline titers in the mRNA cohort were lower than in the subunit cohort. Compared with post-prime, the mean parental NAb titers 14 days post-booster were also significantly higher than the peak titer at D35 (3.2-fold, p-value < 0.05 and 3.8-fold, pvalue < 0.01 for mRNA-primed and subunit-primed cohorts, respectively). A booster dose with CoV2 preS dTM-AS03 adjuvanted vaccine candidates (monovalent or bivalent formulations) also significantly increased parental NAb titers compared with baseline in both cohorts as early as 7 days after injection, and by 14 days, the mean titers were 4.0 log 10 in mRNA-primed (mean fold increase of 370, p-value < 0.001) and 4.4 log 10 in subunit-primed (mean fold-increase of 177, p-value < 0.001) animals. The titers were stable up to D28, and then slightly declined up to D84 (mean titers at 3.3 log 10 and 3.7 log 10 in the mRNA-and subunit-primed cohorts, respectively). In both the mRNA-and subunit-primed cohorts, after the AS03-adjuvanted booster, the parental NAb titers (D7-D28 postboost) were significantly higher than the peak titers post-priming vaccination at D35 (mean fold increase of 21 in the mRNAprimed cohort and 31 in the subunit-primed cohort, p-value < 0.001). There were no statistically significant differences in parental NAb titer increase (from D35 post primary vaccination or from baseline pre-booster) between the various AS03adjuvanted vaccine formulations. In both cohorts, a significant adjuvant effect was observed on the fold increase from baseline to 2 weeks post-booster with CoV2 preS dTM-AS03 (B.1.351) vaccine compared with nonadjuvanted CoV2 preS dTM (B.1.351). AS03 induced a 6.5fold and an 8.1-fold increase (p-value < 0.01) in the mRNAprimed cohort and the subunit-primed cohort, respectively. Up to one month post booster, the parental NAb titers elicited by nonadjuvanted CoV2 preS dTM (B.1.351) booster were all higher than the mean NAb titers of human convalescent sera (2.2 log 10 ), and all AS03-adjuvanted candidate vaccines induced titers above the highest titer observed in human convalescent sera in the subunit-primed cohort (the lowest NAb titers were 3.6 log 10 after the AS03-adjuvanted boost, and the highest NAb titer in human convalescent sera panel was 3.3 log 10 ). Boosting with homologous and heterologous formulations of CoV2 preS dTM led to significant increase in neutralizing antibodies against the Beta variant, with a significant AS03adjuvant effect. We next assessed NAb titers against the Beta variant using the lentivirus-based neutralization assay. After the primary immunization, Beta NAb titers were low to undetectable in the mRNA-primed cohort (mean titer of 1.4 log 10 ) and low in the subunit-primed cohort (mean titer of 1.6 log 10 ) at D35 (Fig. 1c) . Seven months post-prime, Beta NAb titers were undetectable in the mRNA-primed cohort (